Brazil Temporarily Halts Rollout of Butantan Dengue Vaccine Following Reports of Rare Severe Reactions
The Brazilian Ministry of Health and the National Health Surveillance Agency (Anvisa) announced on June 8, 2026, a precautionary suspension of the Butantan-DV dengue vaccine. This decision follows the detection of 42 rare cases involving warning signs among approximately 501,000 individuals who had received the single-dose immunization by the end of May. Three of these cases were classified as serious, including two deaths that remain under investigation. No causal link between the vaccine and these events has been established at this stage.
The suspension applies to the current vaccination strategy targeting primary healthcare professionals and residents aged 15 to 59 in specific municipalities including Botucatu in São Paulo state, Maranguape in Ceará, Nova Lima in Minas Gerais, and the Araguaína region in Tocantins. Vaccination began earlier in 2026 as part of efforts to combat dengue through the Unified Health System (SUS).
Background on the Butantan-DV Vaccine Development and Approval
Butantan-DV, developed by the Instituto Butantan in São Paulo, represents the world's first single-dose dengue vaccine. It is a live attenuated tetravalent formulation designed to protect against all four dengue virus serotypes. Anvisa granted approval in late 2025 following extensive phase 3 clinical trials involving more than 11,000 volunteers across 14 Brazilian states, with follow-up extending up to five years. Clinical data indicated an overall efficacy of around 65 percent against symptomatic dengue and 80.5 percent against severe forms or those with warning signs.
The vaccine was positioned as a significant advancement for mass immunization campaigns due to its single-dose regimen, simplifying logistics compared to multi-dose alternatives. Initial rollout prioritized frontline health workers and select high-risk areas to evaluate real-world performance through pharmacovigilance systems.
Details of the Reported Adverse Events and Ongoing Investigation
Pharmacovigilance monitoring, a standard procedure for new vaccines introduced into the SUS, identified 42 instances of unexpected reactions not observed during clinical trials. These included symptoms such as intense abdominal pain, persistent vomiting, and bleeding. The rate equates to roughly 0.008 percent of doses administered. Among them, three cases required intensive care, with two resulting in fatalities involving a 58-year-old man and a 48-year-old woman. A 38-year-old woman was also hospitalized but later discharged.
Health Minister Alexandre Padilha emphasized during a press conference that the measure is precautionary. Investigations will examine comorbidities, risk factors, and any potential connections, involving municipal, state, and federal surveillance teams alongside expert panels. Batches of the vaccine have been recalled pending further analysis. Authorities stress that storage, transport, and administration processes show no evident issues at this time.
Photo by Total Shape on Unsplash
Context of Dengue Transmission and Broader Control Measures in Brazil
Dengue remains a major public health challenge in Brazil, transmitted primarily by the Aedes aegypti mosquito. The country has seen dramatic reductions in cases and deaths in 2026 compared to the record epidemic of 2024. By late May, probable cases stood at approximately 365,000, reflecting a 94 percent decline, while deaths dropped 97 percent to 178. These improvements stem from intensified vector control, public awareness campaigns, and complementary immunization efforts.
The Ministry of Health continues all other dengue prevention strategies, including breeding site elimination, insecticide distribution, laboratory monitoring of circulating serotypes, and support for states and municipalities. The Qdenga vaccine, another option available through the SUS for children and adolescents aged 10 to 14, remains in use with millions of doses administered.
Stakeholder Perspectives and Public Health Response
Officials from the Ministry of Health, Anvisa, and the Butantan Institute have collaborated closely on the response. The Interinstitutional Committee for Pharmacovigilance of Vaccines and other Immunobiologicals (Cifavi) and the Technical Advisory Chamber on Immunization (Ctai) contributed to the decision. Padilha highlighted the importance of respecting life and science, noting that the surveillance system functioned as intended by detecting the signal early.
Health teams nationwide are reinforcing monitoring for vaccinated individuals, advising vigilance for symptoms up to 21 days post-vaccination and immediate medical attention if warning signs appear. Epidemiological surveillance will intensify focus on recognizing severity indicators and ensuring rapid referrals. Those already immunized are considered protected based on trial evidence, with no change to that assessment.
Implications for Vaccination Strategies and Future Outlook
The temporary pause allows time for thorough investigation without discarding existing doses, which remain in cold storage. Experts note that rare adverse events can emerge post-approval during widespread use, underscoring the value of robust pharmacovigilance. Similar monitoring protocols apply internationally to new vaccines.
Resumption of the Butantan-DV strategy will depend on investigation outcomes and guidance from Anvisa expert panels. In the interim, dengue control relies on established non-vaccine measures and the continued availability of Qdenga for eligible groups. Long-term, the single-dose technology holds promise for scalable protection if safety concerns are resolved.
Public Guidance and Recommendations
Individuals who received the Butantan-DV vaccine should continue monitoring their health and seek care promptly for fever, severe abdominal pain, persistent vomiting, bleeding, dizziness, excessive drowsiness, dehydration signs, or general worsening. After 21 days, the active components are no longer detectable in the body.
Communities are urged to participate actively in vector control by eliminating standing water, maintaining covered water storage, cleaning gutters, and properly disposing of waste. Health professionals receive ongoing training for early diagnosis and patient management.
Global and Regional Context of Dengue Vaccines
Brazil's experience with Butantan-DV adds to the international landscape of dengue immunization. Other licensed vaccines exist, but the single-dose profile offered unique advantages for endemic regions. Ongoing global efforts focus on improving efficacy across serotypes and safety profiles through continued research and post-marketing surveillance.
The precautionary approach aligns with World Health Organization principles emphasizing vigilant monitoring of new health interventions. Brazil's transparent handling of the situation provides a model for balancing innovation with public safety.
